BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 20956465)

  • 41. Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro.
    Cescato R; Waser B; Fani M; Reubi JC
    J Nucl Med; 2011 Dec; 52(12):1886-90. PubMed ID: 22068898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
    Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
    Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
    Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatostatin analogs and radiopeptides in cancer therapy.
    Froidevaux S; Eberle AN
    Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
    Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
    Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
    Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of
    Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
    [TBL] [Abstract][Full Text] [Related]  

  • 50. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
    Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
    J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
    Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
    Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
    Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
    J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of a Fluorescent and Radiolabeled Hybrid Somatostatin Analog In Vitro and in Mice Bearing H69 Neuroendocrine Xenografts.
    Santini C; Kuil J; Bunschoten A; Pool S; de Blois E; Ridwan Y; Essers J; Bernsen MR; van Leeuwen FW; de Jong M
    J Nucl Med; 2016 Aug; 57(8):1289-95. PubMed ID: 27127222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
    Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
    Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
    Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.
    Virgolini I; Patri P; Novotny C; Traub T; Leimer M; Füger B; Li SR; Angelberger P; Raderer M; Wogritsch S; Kurtaran A; Kletter K; Dudczak R
    Ann Oncol; 2001; 12 Suppl 2():S41-5. PubMed ID: 11762351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery.
    Hernandez Vargas S; Kossatz S; Voss J; Ghosh SC; Tran Cao HS; Simien J; Reiner T; Dhingra S; Fisher WE; Azhdarinia A
    Clin Cancer Res; 2019 Jul; 25(14):4332-4342. PubMed ID: 31015345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
    Ginj M; Schmitt JS; Chen J; Waser B; Reubi JC; de Jong M; Schulz S; Maecke HR
    Chem Biol; 2006 Oct; 13(10):1081-90. PubMed ID: 17052612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.